A personalised medicine specialist has raised 拢50 million in Series B funding.
Headquartered at the Chesterford Research Park near Cambridge, Microbiotica has developed technology which uses the body鈥檚 trillions of resident bacteria – known as the microbiome – to discover and develop therapeutic medicines and biomarkers for a range of disorders and diseases.聽
The company鈥檚 current areas of focus are cancer immunotherapy and inflammatory bowel disease and it has established major clinical and academic partnerships in these areas.
The round was led by Flerie Invest and Tencent, and included British Patient Capital, Cambridge Innovation Capital, IP Group and Seventure Partners.
鈥淭his major fundraise is a substantial validation of both our team and our world-leading technology,鈥� said Mike Romanos, co-founder and CEO of Microbiotica.
鈥淲e are fortunate to have the support from new and current investors who have recognised the importance of the microbiome鈥檚 therapeutic potential and Microbiotica鈥檚 unique capabilities.聽
鈥淲ith this additional investment, we will be able to conduct clinical trials with our lead products in immuno-oncology and ulcerative colitis. We will also expand our portfolio of microbiome-based products which have the potential to benefit patients globally.鈥�
Judith Hartley, CEO of British Patient Capital, added: 鈥淢icrobiotica is a highly innovative UK company operating in the very important field of microbiome biology.
鈥淭hrough its bioinformatics platform, it is generating therapeutic treatments targeting immuno-oncology and ulcerative colitis. It has a number of drug development programmes that are progressing to clinical trials.聽
鈥淏ritish Patient Capital, through our Future Fund: Breakthrough programme, is proud to support this world-class team as they continue to explore and commercialise this exciting new area of medicine.鈥�